Tumor necrosis factor-alpha-converting enzyme activities and tumor-associated macrophages in breast cancer

Immunologic Research

Volumn 58, Issue 1, 2014, Pages 87-100

  Rego, Stephen L ^a   Helms, Rachel S ^a   Dréau, Didier ^a  

^a UNIVERSITY OF NORTH CAROLINA AT CHARLOTTE   (United States)

Author keywords

Breast cancer; Ectodomain shedding; Macrophages; Tumor necrosis factor alpha converting enzyme

Indexed keywords

ADERBASIB; COLONY STIMULATING FACTOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITOR; TUMOR NECROSIS FACTOR RECEPTOR; VASCULAR CELL ADHESION MOLECULE 1;

ANGIOGENESIS; ARTICLE; AUTOCRINE EFFECT; BREAST CANCER; CANCER SURVIVAL; CELL INFILTRATION; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; LIVER TOXICITY; MACROPHAGE; MACROPHAGE ACTIVATION; MAMMARY GLAND; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL; TUMOR GROWTH; TUMOR INVASION; TUMOR MICROENVIRONMENT;

ADAM PROTEINS; ANIMALS; BREAST NEOPLASMS; ENZYME ACTIVATION; ENZYME INHIBITORS; FEMALE; HUMANS; MACROPHAGES; PHENOTYPE;

EID: 84893609701     PISSN: 0257277X     EISSN: 15590755     Source Type: Journal    
DOI: 10.1007/s12026-013-8434-7     Document Type: Article

References (187)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-74. doi: 10.1016/j.cell.2011.02.013.
2. Reddy BY, Lim PK, Silverio K, Patel SA, Won BW, Rameshwar P. The microenvironmental effect in the progression, metastasis, and dormancy of breast cancer: a model system within bone marrow. Int J Breast Cancer. 2012;2012:721659. doi: 10.1155/2012/721659.
3. Beck AH, Espinosa I, Edris B, Li R, Montgomery K, Zhu S, et al. The macrophage colony-stimulating factor 1 response signature in breast carcinoma. Clin Cancer Res. 2009;15(3):778-87. doi: 10.1158/1078-0432.CCR-08-1283.
4. Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H, et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med. 2008;14(5):518-27. doi: 10.1038/nm1764.
5. Talmadge JE, Donkor M, Scholar E. Inflammatory cell infiltration of tumors: Jekyll or Hyde. Cancer Metastasis Rev. 2007;26(3-4):373-400. doi: 10.1007/s10555-007-9072-0.
6. Lin EY, Nguyen AV, Russell RG, Pollard JW. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med. 2001;193(6):727-40.
7. Bonta IL, Ben-Efraim S. Involvement of inflammatory mediators in macrophage antitumor activity. J Leukoc Biol. 1993;54(6):613-26.
8. Herberman RB, Holden HT, Djeu JY, Jerrells TR, Varesio L, Tagliabue A, et al. Macrophages as regulators of immune responses against tumors. Adv Exp Med Biol. 1979;121B:361-79.
9. O'Sullivan C, Lewis CE. Tumour-associated leucocytes: friends or foes in breast carcinoma. J Pathol. 1994;172(3):229-35. doi: 10.1002/path.1711720302.
10. Ben-Baruch A. Host microenvironment in breast cancer development: inflammatory cells, cytokines and chemokines in breast cancer progression: reciprocal tumor-microenvironment interactions. Breast Cancer Res. 2003;5(1):31-6.
11. Chen Q, Zhang XH, Massague J. Macrophage binding to receptor VCAM-1 transmits survival signals in breast cancer cells that invade the lungs. Cancer Cell. 2011;20(4):538-49. doi: 10.1016/j.ccr.2011.08.025.
12. Goswami S, Sahai E, Wyckoff JB, Cammer M, Cox D, Pixley FJ, et al. Macrophages promote the invasion of breast carcinoma cells via a colony-stimulating factor-1/epidermal growth factor paracrine loop. Cancer Res. 2005;65(12):5278-83. doi: 10.1158/0008-5472.CAN-04-1853.
13. Kluger HM, Dolled-Filhart M, Rodov S, Kacinski BM, Camp RL, Rimm DL. Macrophage colony-stimulating factor-1 receptor expression is associated with poor outcome in breast cancer by large cohort tissue microarray analysis. Clin Cancer Res. 2004;10(1 Pt 1):173-7.
14. Lin CW, Shen SC, Ko CH, Lin HY, Chen YC. Reciprocal activation of macrophages and breast carcinoma cells by nitric oxide and colony-stimulating factor-1. Carcinogenesis. 2010;31(12):2039-48. doi: 10.1093/carcin/bgq172.
15. Wyckoff J, Wang W, Lin EY, Wang Y, Pixley F, Stanley ER, et al. A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. Cancer Res. 2004;64(19):7022-9. doi: 10.1158/0008-5472.CAN-04-1449.
16. Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol. 2010;11(10):889-96. doi: 10.1038/ni.1937.
17. Lewis CE, Hughes R. Inflammation and breast cancer. Microenvironmental factors regulating macrophage function in breast tumours: hypoxia and angiopoietin-2. Breast Cancer Res. 2007;9(3):209. doi: 10.1186/bcr1679.
18. Mantovani A, Sica A, Locati M. Macrophage polarization comes of age. Immunity. 2005;23(4):344-6. doi: 10.1016/j.immuni.2005.10.001.
19. Arribas J, Esselens C. ADAM17 as a therapeutic target in multiple diseases. Curr Pharm Des. 2009;15(20):2319-35.
20. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature. 1997;385(6618):729-33. doi: 10.1038/385729a0.
21. Kenny PA, Bissell MJ. Targeting TACE-dependent EGFR ligand shedding in breast cancer. J Clin Invest. 2007;117(2):337-45. doi: 10.1172/JCI29518.
22. Scheller J, Chalaris A, Garbers C, Rose-John S. ADAM17: a molecular switch to control inflammation and tissue regeneration. Trends Immunol. 2011;32(8):380-7. doi: 10.1016/j.it.2011.05.005.
23. DasGupta S, Murumkar PR, Giridhar R, Yadav MR. Current perspective of TACE inhibitors: a review. Bioorg Med Chem. 2009;17(2):444-59. doi: 10.1016/j.bmc.2008.11.067.
24. Duffy MJ, Mullooly M, O'Donovan N, Sukor S, Crown J, Pierce A, et al. The ADAMs family of proteases: new biomarkers and therapeutic targets for cancer? Clin Proteomics. 2011;8(1):9. doi: 10.1186/1559-0275-8-9.
25. Seals DF, Courtneidge SA. The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev. 2003;17(1):7-30. doi: 10.1101/gad.1039703.
26. Erreni M, Mantovani A, Allavena P. Tumor-associated macrophages (TAM) and inflammation in colorectal cancer. Cancer Microenviron. 2011;4(2):141-54. doi: 10.1007/s12307-010-0052-5.
27. Leek RD, Harris AL. Tumor-associated macrophages in breast cancer. J Mammary Gland Biol Neoplasia. 2002;7(2):177-89.
28. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002;23(11):549-55.
29. Pollard JW. Macrophages define the invasive microenvironment in breast cancer. J Leukoc Biol. 2008;84(3):623-30. doi: 10.1189/jlb.1107762.
30. Tjiu JW, Chen JS, Shun CT, Lin SJ, Liao YH, Chu CY, et al. Tumor-associated macrophage-induced invasion and angiogenesis of human basal cell carcinoma cells by cyclooxygenase-2 induction. J Invest Dermatol. 2009;129(4):1016-25. doi: 10.1038/jid.2008.310.
31. Mahmoud SM, Lee AH, Paish EC, Macmillan RD, Ellis IO, Green AR. Tumour-infiltrating macrophages and clinical outcome in breast cancer. J Clin Pathol. 2012;65(2):159-63. doi: 10.1136/jclinpath-2011-200355.
32. Leek RD, Lewis CE, Whitehouse R, Greenall M, Clarke J, Harris AL. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res. 1996;56(20):4625-9.
33. Bonde AK, Tischler V, Kumar S, Soltermann A, Schwendener RA. Intratumoral macrophages contribute to epithelial-mesenchymal transition in solid tumors. BMC Cancer. 2012;12:35. doi: 10.1186/1471-2407-12-35.
34. Yona S, Jung S. Monocytes: subsets, origins, fates and functions. Curr Opin Hematol. 2010;17(1):53-9. doi: 10.1097/MOH.0b013e3283324f80.
35. Chomarat P, Banchereau J, Davoust J, Palucka AK. IL-6 switches the differentiation of monocytes from dendritic cells to macrophages. Nat Immunol. 2000;1(6):510-4. doi: 10.1038/82763.
36. Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell. 2006;124(2):263-6. doi: 10.1016/j.cell.2006.01.007.
37. Gazzaniga S, Bravo AI, Guglielmotti A, van Rooijen N, Maschi F, Vecchi A, et al. Targeting tumor-associated macrophages and inhibition of MCP-1 reduce angiogenesis and tumor growth in a human melanoma xenograft. J Invest Dermatol. 2007;127(8):2031-41. doi: 10.1038/sj.jid.5700827.
38. Lin EY, Pollard JW. Macrophages: modulators of breast cancer progression. Novartis Found Symp. 2004;256:158-68; discussion 68-72, 259-69.
39. Mantovani A, Sica A, Locati M. New vistas on macrophage differentiation and activation. Eur J Immunol. 2007;37(1):14-6. doi: 10.1002/eji.200636910.
40. Tran TM, Temkin V, Shi B, Pagliari L, Daniel S, Ferran C, et al. TNFalpha-induced macrophage death via caspase-dependent and independent pathways. Apoptosis. 2009;14(3):320-32. doi: 10.1007/s10495-009-0311-4.
41. Gooz M. ADAM-17: the enzyme that does it all. Crit Rev Biochem Mol Biol. 2010;45(2):146-69. doi: 10.3109/10409231003628015.
42. Fong KP, Barry C, Tran AN, Traxler EA, Wannemacher KM, Tang HY, et al. Deciphering the human platelet sheddome. Blood. 2011;117(1):e15-26. doi: 10.1182/blood-2010-05-283838.
43. Franovic A, Robert I, Smith K, Kurban G, Pause A, Gunaratnam L, et al. Multiple acquired renal carcinoma tumor capabilities abolished upon silencing of ADAM17. Cancer Res. 2006;66(16):8083-90. doi: 10.1158/0008-5472.CAN-06-1595.
44. McGowan PM, Ryan BM, Hill AD, McDermott E, O'Higgins N, Duffy MJ. ADAM-17 expression in breast cancer correlates with variables of tumor progression. Clin Cancer Res. 2007;13(8):2335-43. doi: 10.1158/1078-0432.CCR-06-2092.
45. Takamune Y, Ikebe T, Nagano O, Shinohara M. Involvement of NF-kappaB-mediated maturation of ADAM-17 in the invasion of oral squamous cell carcinoma. Biochem Biophys Res Commun. 2008;365(2):393-8. doi: 10.1016/j.bbrc.2007.11.010.
46. Zheng X, Jiang F, Katakowski M, Zhang ZG, Lu QE, Chopp M. ADAM17 promotes breast cancer cell malignant phenotype through EGFR-PI3 K-AKT activation. Cancer Biol Ther. 2009;8(11):1045-54.
47. Lendeckel U, Kohl J, Arndt M, Carl-McGrath S, Donat H, Rocken C. Increased expression of ADAM family members in human breast cancer and breast cancer cell lines. J Cancer Res Clin Oncol. 2005;131(1):41-8. doi: 10.1007/s00432-004-0619-y.
48. Zhang Y, Xu J, Levin J, Hegen M, Li G, Robertshaw H, et al. Identification and characterization of 4-[[4-(2-butynyloxy)phenyl]sulfonyl]-N- hydroxy-2,2-dimethyl-(3S)thiomorpholinecar boxamide (TMI-1), a novel dual tumor necrosis factor-alpha-converting enzyme/matrix metalloprotease inhibitor for the treatment of rheumatoid arthritis. J Pharmacol Exp Ther. 2004;309(1):348-55. doi: 10.1124/jpet.103.059675.
49. Grootveld M, McDermott MF. BMS-561392. Bristol-Myers Squibb. Curr Opin Investig Drugs. 2003;4(5):598-602.
50. Sternlicht MD, Sunnarborg SW. The ADAM17-amphiregulin-EGFR axis in mammary development and cancer. J Mammary Gland Biol Neoplasia. 2008;13(2):181-94. doi: 10.1007/s10911-008-9084-6.
51. Sternlicht MD, Sunnarborg SW, Kouros-Mehr H, Yu Y, Lee DC, Werb Z. Mammary ductal morphogenesis requires paracrine activation of stromal EGFR via ADAM17-dependent shedding of epithelial amphiregulin. Development. 2005;132(17):3923-33. doi: 10.1242/dev.01966.
52. Patel IR, Attur MG, Patel RN, Stuchin SA, Abagyan RA, Abramson SB, et al. TNF-alpha convertase enzyme from human arthritis-affected cartilage: isolation of cDNA by differential display, expression of the active enzyme, and regulation of TNF-alpha. J Immunol. 1998;160(9):4570-9.
53. Moss ML, Sklair-Tavron L, Nudelman R. Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis. Nat Clin Pract Rheumatol. 2008;4(6):300-9. doi: 10.1038/ncprheum0797.
54. Amin AR. Regulation of tumor necrosis factor-alpha and tumor necrosis factor converting enzyme in human osteoarthritis. Osteoarthr Cartil. 1999;7(4):392-4. doi: 10.1053/joca 1998.0221.
55. Bohgaki T, Amasaki Y, Nishimura N, Bohgaki M, Yamashita Y, Nishio M, et al. Up regulated expression of tumour necrosis factor alpha converting enzyme in peripheral monocytes of patients with early systemic sclerosis. Ann Rheum Dis. 2005;64(8):1165-73. doi: 10.1136/ard.2004.030338.
56. Ohta S, Harigai M, Tanaka M, Kawaguchi Y, Sugiura T, Takagi K, et al. Tumor necrosis factor-alpha (TNF-alpha) converting enzyme contributes to production of TNF-alpha in synovial tissues from patients with rheumatoid arthritis. J Rheumatol. 2001;28(8):1756-63.
57. Wang Y, Herrera AH, Li Y, Belani KK, Walcheck B. Regulation of mature ADAM17 by redox agents for L-selectin shedding. J Immunol. 2009;182(4):2449-57. doi: 10.4049/jimmunol.0802770.
58. Ermert M, Pantazis C, Duncker HR, Grimminger F, Seeger W, Ermert L. In situ localization of TNFalpha/beta, TACE and TNF receptors TNF-R1 and TNF-R2 in control and LPS-treated lung tissue. Cytokine. 2003;22(3-4):89-100.
59. Koenen RR, Pruessmeyer J, Soehnlein O, Fraemohs L, Zernecke A, Schwarz N, et al. Regulated release and functional modulation of junctional adhesion molecule A by disintegrin metalloproteinases. Blood. 2009;113(19):4799-809. doi: 10.1182/blood-2008-04-152330.
60. Goddard DR, Bunning RA, Woodroofe MN. Astrocyte and endothelial cell expression of ADAM 17 (TACE) in adult human CNS. Glia. 2001;34(4):267-71. doi: 10.1002/glia.1060.
61. Fata JE, Werb Z, Bissell MJ. Regulation of mammary gland branching morphogenesis by the extracellular matrix and its remodeling enzymes. Breast Cancer Res. 2004;6(1):1-11. doi: 10.1186/bcr634.
62. Sternlicht MD. Key stages in mammary gland development: the cues that regulate ductal branching morphogenesis. Breast Cancer Res. 2006;8(1):201. doi: 10.1186/bcr1368.
63. Bell JH, Herrera AH, Li Y, Walcheck B. Role of ADAM17 in the ectodomain shedding of TNF-alpha and its receptors by neutrophils and macrophages. J Leukoc Biol. 2007;82(1):173-6. doi: 10.1189/jlb.0307193.
64. Ingman WV, Wyckoff J, Gouon-Evans V, Condeelis J, Pollard JW. Macrophages promote collagen fibrillogenesis around terminal end buds of the developing mammary gland. Dev Dyn. 2006;235(12):3222-9. doi: 10.1002/dvdy.20972.
65. McGowan PM, Mullooly M, Caiazza F, Sukor S, Madden SF, Maguire AA, et al. ADAM-17: a novel therapeutic target for triple negative breast cancer. Ann Oncol. 2012;. doi: 10.1093/annonc/mds279.
66. Mohammed FF, Smookler DS, Khokha R. Metalloproteinases, inflammation, and rheumatoid arthritis. Ann Rheum Dis. 2003;62 Suppl 2:ii43-7.
67. Lee AM, Diasio RB. ADAM-17: a target to increase chemotherapeutic efficacy in colorectal cancer? Clin Cancer Res. 2010;16(13):3319-21. doi: 10.1158/1078-0432.CCR-10-1059.
68. Sunnarborg SW, Hinkle CL, Stevenson M, Russell WE, Raska CS, Peschon JJ, et al. Tumor necrosis factor-alpha converting enzyme (TACE) regulates epidermal growth factor receptor ligand availability. J Biol Chem. 2002;277(15):12838-45. doi: 10.1074/jbc.M112050200.
69. Reid A, Vidal L, Shaw H, de Bono J. Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu). Eur J Cancer. 2007;43(3):481-9. doi: 10.1016/j.ejca.2006. 11.007.
70. Irwin ME, Bohin N, Boerner JL. Src family kinases mediate epidermal growth factor receptor signaling from lipid rafts in breast cancer cells. Cancer Biol Ther. 2011;12(8):718-26. doi: 10.4161/cbt.12.8.16907.
71. Pruessmeyer J, Ludwig A. The good, the bad and the ugly substrates for ADAM10 and ADAM17 in brain pathology, inflammation and cancer. Semin Cell Dev Biol. 2009;20(2):164-74. doi: 10.1016/j.semcdb.2008.09.005.
72. Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer. 2009;9(5):361-71. doi: 10.1038/nrc2628.
73. Mosser DM. The many faces of macrophage activation. J Leukoc Biol. 2003;73(2):209-12.
74. Lin EY, Gouon-Evans V, Nguyen AV, Pollard JW. The macrophage growth factor CSF-1 in mammary gland development and tumor progression. J Mammary Gland Biol Neoplasia. 2002;7(2):147-62.
75. Green CE, Liu T, Montel V, Hsiao G, Lester RD, Subramaniam S, et al. Chemoattractant signaling between tumor cells and macrophages regulates cancer cell migration, metastasis and neovascularization. PLoS ONE. 2009;4(8):e6713. doi: 10.1371/journal.pone.0006713.
76. Pixley FJ, Stanley ER. CSF-1 regulation of the wandering macrophage: complexity in action. Trends Cell Biol. 2004;14(11):628-38. doi: 10.1016/j.tcb.2004.09.016.
77. Lin EY, Li JF, Gnatovskiy L, Deng Y, Zhu L, Grzesik DA, et al. Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res. 2006;66(23):11238-46. doi: 10.1158/0008-5472.CAN-06-1278.
78. Rego S, Helms R, Kidiyoor A, Mukherjee P, Dréau D. MCSF shed by breast tumor cells through TACE activities stimulates pro-angiogenic macrophages. Center for biomedical research annual retreat. 2013.
79. Wyckoff JB, Wang Y, Lin EY, Li JF, Goswami S, Stanley ER, et al. Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. Cancer Res. 2007;67(6):2649-56. doi: 10.1158/0008-5472.CAN-06-1823.
80. Rivas MA, Carnevale RP, Proietti CJ, Rosemblit C, Beguelin W, Salatino M, et al. TNF alpha acting on TNFR1 promotes breast cancer growth via p42/P44 MAPK, JNK, Akt and NF-kappa B-dependent pathways. Exp Cell Res. 2008;314(3):509-29. doi: 10.1016/j.yexcr.2007.10.005.
81. Balkwill F. TNF-alpha in promotion and progression of cancer. Cancer Metastasis Rev. 2006;25(3):409-16. doi: 10.1007/s10555-006-9005-3.
82. Helson L, Helson C, Green S. Effects of murine tumor necrosis factor on heterotransplanted human tumors. Exp Cell Biol. 1979;47(1):53-60.
83. Watanabe N, Niitsu Y, Umeno H, Kuriyama H, Neda H, Yamauchi N, et al. Toxic effect of tumor necrosis factor on tumor vasculature in mice. Cancer Res. 1988;48(8):2179-83.
84. Shubayev VI, Angert M, Dolkas J, Campana WM, Palenscar K, Myers RR. TNFalpha-induced MMP-9 promotes macrophage recruitment into injured peripheral nerve. Mol Cell Neurosci. 2006;31(3):407-15. doi: 10.1016/j.mcn.2005.10.011.
85. Karabela SP, Kairi CA, Magkouta S, Psallidas I, Moschos C, Stathopoulos I, et al. Neutralization of tumor necrosis factor bioactivity ameliorates urethane-induced pulmonary oncogenesis in mice. Neoplasia. 2011;13(12):1143-51.
86. Mohamed-Ali V, Goodrick S, Bulmer K, Holly JM, Yudkin JS, Coppack SW. Production of soluble tumor necrosis factor receptors by human subcutaneous adipose tissue in vivo. Am J Physiol. 1999;277(6 Pt 1):E971-5.
87. Rego SL, Swamydas M, Kidiyoor A, Helms R, De Piante A, Lance AL, et al. Soluble tumor necrosis factor receptors shed by breast tumor cells inhibit macrophage chemotaxis. J Interferon Cytokine Res. 2013;. doi: 10.1089/jir.2013.0009.
88. Silva HC, Garcao F, Coutinho EC, De Oliveira CF, Regateiro FJ. Soluble VCAM-1 and E-selectin in breast cancer: relationship with staging and with the detection of circulating cancer cells. Neoplasma. 2006;53(6):538-43.
89. Kostler WJ, Tomek S, Brodowicz T, Budinsky AC, Flamm M, Hejna M, et al. Soluble ICAM-1 in breast cancer: clinical significance and biological implications. Cancer Immunol Immunother. 2001;50(9):483-90.
90. Nakata B, Hori T, Sunami T, Ogawa Y, Yashiro M, Maeda K, et al. Clinical significance of serum soluble intercellular adhesion molecule 1 in gastric cancer. Clin Cancer Res. 2000;6(3):1175-9.
91. Rosette C, Roth RB, Oeth P, Braun A, Kammerer S, Ekblom J, et al. Role of ICAM1 in invasion of human breast cancer cells. Carcinogenesis. 2005;26(5):943-50. doi: 10.1093/carcin/bgi070.
92. Byrne GJ, Ghellal A, Iddon J, Blann AD, Venizelos V, Kumar S, et al. Serum soluble vascular cell adhesion molecule-1: role as a surrogate marker of angiogenesis. J Natl Cancer Inst. 2000;92(16):1329-36.
93. Chen Q, Massague J. Molecular pathways: vcam-1 as a potential therapeutic target in metastasis. Clin Cancer Res. 2012;18(20):5520-5. doi: 10.1158/1078-0432.CCR-11-2904.
94. Lu X, Mu E, Wei Y, Riethdorf S, Yang Q, Yuan M, et al. VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging alpha4beta1-positive osteoclast progenitors. Cancer Cell. 2011;20(6):701-14. doi: 10.1016/j.ccr.2011.11.002.
95. Cybulsky MI, Iiyama K, Li H, Zhu S, Chen M, Iiyama M, et al. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Invest. 2001;107(10):1255-62. doi: 10.1172/JCI11871.
96. Nath D, Hartnell A, Happerfield L, Miles DW, Burchell J, Taylor-Papadimitriou J, et al. Macrophage-tumour cell interactions: identification of MUC1 on breast cancer cells as a potential counter-receptor for the macrophage-restricted receptor, sialoadhesin. Immunology. 1999;98(2):213-9.
97. Hemmerlein B, Scherbening J, Kugler A, Radzun HJ. Expression of VCAM-1, ICAM-1, E- and P-selectin and tumour-associated macrophages in renal cell carcinoma. Histopathology. 2000;37(1):78-83.
98. Yu JL, Rak JW. Host microenvironment in breast cancer development: inflammatory and immune cells in tumour angiogenesis and arteriogenesis. Breast Cancer Res. 2003;5(2):83-8.
99. Hayashi T, Takahashi T, Motoya S, Ishida T, Itoh F, Adachi M, et al. MUC1 mucin core protein binds to the domain 1 of ICAM-1. Digestion. 2001;63(Suppl 1):87-92.
100. Patel SS, Thiagarajan R, Willerson JT, Yeh ET. Inhibition of alpha4 integrin and ICAM-1 markedly attenuate macrophage homing to atherosclerotic plaques in ApoE-deficient mice. Circulation. 1998;97(1):75-81.
101. Geng Y, Yeh K, Takatani T, King MR. Three to tango: MUC1 as a ligand for both E-selectin and ICAM-1 in the breast cancer metastatic cascade. Front Oncol. 2012;2:76. doi: 10.3389/fonc.2012.00076.
102. Schaff U, Mattila PE, Simon SI, Walcheck B. Neutrophil adhesion to E-selectin under shear promotes the redistribution and co-clustering of ADAM17 and its proteolytic substrate L-selectin. J Leukoc Biol. 2008;83(1):99-105. doi: 10.1189/jlb.0507304.
103. Rahn JJ, Chow JW, Horne GJ, Mah BK, Emerman JT, Hoffman P, et al. MUC1 mediates transendothelial migration in vitro by ligating endothelial cell ICAM-1. Clin Exp Metastasis. 2005;22(6):475-83. doi: 10.1007/s10585-005-3098-x.
104. Ghislin S, Obino D, Middendorp S, Boggetto N, Alcaide-Loridan C, Deshayes F. LFA-1 and ICAM-1 expression induced during melanoma-endothelial cell co-culture favors the transendothelial migration of melanoma cell lines in vitro. BMC Cancer. 2012;12:455. doi: 10.1186/1471-2407-12-455.
105. Rego SL, Helms RS, De Piante A, Kidiyoor A, Lance A, Mukherjee P et al. TNFRs shed by tumor cells inhibit the migration of macrophages. AACR annual meeting 2012. 2012.
106. Knupfer H, Preiss R. Lack of knowledge: breast cancer and the soluble interleukin-6 receptor. Breast Care. 2010;5(3):177-80.
107. Salgado R, Junius S, Benoy I, Van Dam P, Vermeulen P, Van Marck E, et al. Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. Int J Cancer. 2003;103(5):642-6. doi: 10.1002/ijc.10833.
108. Won HS, Kim YA, Lee JS, Jeon EK, An HJ, Sun DS, et al. Soluble interleukin-6 receptor is a prognostic marker for relapse-free survival in estrogen receptor-positive breast cancer. Cancer Invest. 2013;. doi: 10.3109/07357907.2013.826239.
109. Rose-John S. IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int J Biol Sci. 2012;8(9):1237-47. doi: 10.7150/ijbs.4989.
110. Matsumoto S, Hara T, Mitsuyama K, Yamamoto M, Tsuruta O, Sata M, et al. Essential roles of IL-6 trans-signaling in colonic epithelial cells, induced by the IL-6/soluble-IL-6 receptor derived from lamina propria macrophages, on the development of colitis-associated premalignant cancer in a murine model. J Immunol. 2010;184(3):1543-51. doi: 10.4049/jimmunol.0801217.
111. Berishaj M, Gao SP, Ahmed S, Leslie K, Al-Ahmadie H, Gerald WL, et al. Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer. Breast Cancer Res. 2007;9(3):R32. doi: 10.1186/bcr1680.
112. Shostak K, Chariot A. NF-kappaB, stem cells and breast cancer: the links get stronger. Breast Cancer Res. 2011;13(4):214. doi: 10.1186/bcr2886.
113. Vainchenker W, Constantinescu SN. JAK/STAT signaling in hematological malignancies. Oncogene. 2013;32(21):2601-13. doi: 10.1038/onc.2012.347.
114. Hynes NE, Watson CJ. Mammary gland growth factors: roles in normal development and in cancer. Cold Spring Harb Perspect Biol. 2010;2(8):a003186. doi: 10.1101/cshperspect.a003186.
115. Kujawski M, Kortylewski M, Lee H, Herrmann A, Kay H, Yu H. Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J Clin Invest. 2008;118(10):3367-77. doi: 10.1172/JCI35213.
116. Hajishengallis G, Lambris JD. Microbial manipulation of receptor crosstalk in innate immunity. Nat Rev Immunol. 2011;11(3):187-200. doi: 10.1038/nri2918.
117. Gooz P, Gooz M, Baldys A, Hoffman S. ADAM-17 regulates endothelial cell morphology, proliferation, and in vitro angiogenesis. Biochem Biophys Res Commun. 2009;380(1):33-8. doi: 10.1016/j.bbrc.2009.01.013.
118. Weskamp G, Mendelson K, Swendeman S, Le Gall S, Ma Y, Lyman S, et al. Pathological neovascularization is reduced by inactivation of ADAM17 in endothelial cells but not in pericytes. Circ Res. 2010;106(5):932-40. doi: 10.1161/CIRCRESAHA.109.207415.
119. Garton KJ, Gough PJ, Philalay J, Wille PT, Blobel CP, Whitehead RH, et al. Stimulated shedding of vascular cell adhesion molecule 1 (VCAM-1) is mediated by tumor necrosis factor-alpha-converting enzyme (ADAM 17). J Biol Chem. 2003;278(39):37459-64. doi: 10.1074/jbc.M305877200.
120. McGowan PM, McKiernan E, Bolster F, Ryan BM, Hill AD, McDermott EW, et al. ADAM-17 predicts adverse outcome in patients with breast cancer. Ann Oncol. 2008;19(6):1075-81. doi: 10.1093/annonc/mdm609.
121. Merchant NB, Voskresensky I, Rogers CM, Lafleur B, Dempsey PJ, Graves-Deal R, et al. TACE/ADAM-17: a component of the epidermal growth factor receptor axis and a promising therapeutic target in colorectal cancer. Clin Cancer Res. 2008;14(4):1182-91. doi: 10.1158/1078-0432.CCR-07-1216.
122. Zhang Y, Hegen M, Xu J, Keith JC Jr, Jin G, Du X, et al. Characterization of (2R, 3S)-2-([[4-(2-butynyloxy)phenyl]sulfonyl]amino)-N,3- dihydroxybutanamide, a potent and selective inhibitor of TNF-alpha converting enzyme. Int Immunopharmacol. 2004;4(14):1845-57. doi: 10.1016/j.intimp.2004.08. 003.
123. Gonzales PE, Solomon A, Miller AB, Leesnitzer MA, Sagi I, Milla ME. Inhibition of the tumor necrosis factor-alpha-converting enzyme by its pro domain. J Biol Chem. 2004;279(30):31638-45. doi: 10.1074/jbc.M401311200.
124. Infante J BH, Lewis N, et al. A multicenter phase Ib study of the safety, pharmacokinetics, biological activity and clinical efficacy of INCB7839, a potent and selective inhibitor of ADAM10 and ADAM17. Breast Cancer Res Treat 2007;106(Supp1):S269.(Supp1):S269.
125. Levin JI, Chen JM, Laakso LM, Du M, Schmid J, Xu W, et al. Acetylenic TACE inhibitors. Part 3: thiomorpholine sulfonamide hydroxamates. Bioorg Med Chem Lett. 2006;16(6):1605-9. doi: 10.1016/j.bmcl.2005.12.020.
126. Thabet MM, Huizinga TW. Drug evaluation: apratastat, a novel TACE/MMP inhibitor for rheumatoid arthritis. Curr Opin Investig Drugs. 2006;7(11):1014-9.
127. Huang Z, Zhang Z, Jiang Y, Zhang D, Chen J, Dong L, et al. Targeted delivery of oligonucleotides into tumor-associated macrophages for cancer immunotherapy. J Control Release. 2012;158(2):286-92. doi: 10.1016/j.jconrel. 2011.11.013.
128. Rolny C, Mazzone M, Tugues S, Laoui D, Johansson I, Coulon C, et al. HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell. 2011;19(1):31-44. doi: 10.1016/j.ccr.2010.11.009.
129. Tyagi A, Singh RP, Ramasamy K, Raina K, Redente EF, Dwyer-Nield LD, et al. Growth inhibition and regression of lung tumors by silibinin: modulation of angiogenesis by macrophage-associated cytokines and nuclear factor-kappaB and signal transducers and activators of transcription 3. Cancer Prev Res. 2009;2(1):74-83. doi: 10.1158/1940-6207.CAPR-08-0095.
130. Anthony SP, Puzanov PS, Lin KB, Nolop B, West DD. Pharmacodynamic activity demonstrated in phase I for PLX3397, a selective inhibitor of FMS and Kit. 2011 ASCO annual meeting. 2011;3093.
131. DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 2011;1(1):54-67. doi: 10.1158/2159-8274.CD-10-0028.
132. Rugo H. Phase Ib/II study of PLX 3397 and eribulin in patients with metastatic breast cancer. clinicaltrialgov. 2013;NCT01596751.
133. Paterson AH, Anderson SJ, Lembersky BC, Fehrenbacher L, Falkson CI, King KM, et al. Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial. Lancet Oncol. 2012;13(7):734-42. doi: 10.1016/S1470-2045(12)70226-7.
134. Muraoka-Cook RS, Sandahl M, Hunter D, Miraglia L, Earp HS 3rd. Prolactin and ErbB4/HER4 signaling interact via Janus kinase 2 to induce mammary epithelial cell gene expression differentiation. Mol Endocrinol. 2008;22(10):2307-21. doi: 10.1210/me.2008-0055.
135. Wilson KJ, Gilmore JL, Foley J, Lemmon MA, Riese DJ 2nd. Functional selectivity of EGF family peptide growth factors: implications for cancer. Pharmacol Ther. 2009;122(1):1-8. doi: 10.1016/j.pharmthera.2008.11.008.
136. Miyata K, Yotsumoto F, Nam SO, Kuroki M, Miyamoto S. Regulatory mechanisms of the HB-EGF autocrine loop in inflammation, homeostasis, development and cancer. Anticancer Res. 2012;32(6):2347-52.
137. Stein T, Salomonis N, Gusterson BA. Mammary gland involution as a multi-step process. J Mammary Gland Biol Neoplasia. 2007;12(1):25-35. doi: 10.1007/s10911-007-9035-7.
138. Li CW, Xia W, Huo L, Lim SO, Wu Y, Hsu JL, et al. Epithelial-mesenchymal transition induced by TNF-alpha requires NF-kappaB-mediated transcriptional upregulation of Twist1. Cancer Res. 2012;72(5):1290-300. doi: 10.1158/0008-5472.CAN-11-3123.
139. Pitroda SP, Zhou T, Sweis RF, Filippo M, Labay E, Beckett MA, et al. Tumor endothelial inflammation predicts clinical outcome in diverse human cancers. PLoS ONE. 2012;7(10):e46104. doi: 10.1371/journal.pone.0046104.
140. Kamel M, Shouman S, El-Merzebany M, Kilic G, Veenstra T, Saeed M, et al. Effect of tumour necrosis factor-alpha on estrogen metabolic pathways in breast cancer cells. J Cancer. 2012;3:310-21. doi: 10.7150/jca.4584.
141. White GE, Greaves DR. Fractalkine: one chemokine, many functions. Blood. 2009;113(4):767-8. doi: 10.1182/blood-2008-11-189860.
142. Park MH, Lee JS, Yoon JH. High expression of CX3CL1 by tumor cells correlates with a good prognosis and increased tumor-infiltrating CD8+ T cells, natural killer cells, and dendritic cells in breast carcinoma. J Surg Oncol. 2012;106(4):386-92. doi: 10.1002/jso.23095.
143. Reed JR, Stone MD, Beadnell TC, Ryu Y, Griffin TJ, Schwertfeger KL.
144. Peschon JJ, Torrance DS, Stocking KL, Glaccum MB, Otten C, Willis CR, et al. TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation. J Immunol. 1998;160(2):943-52.
145. Clarkson RW, Wayland MT, Lee J, Freeman T, Watson CJ. Gene expression profiling of mammary gland development reveals putative roles for death receptors and immune mediators in post-lactational regression. Breast Cancer Res. 2004;6(2):R92-109. doi: 10.1186/bcr754.
146. Rovida E, Paccagnini A, Del Rosso M, Peschon J, Dello Sbarba P. TNF-alpha-converting enzyme cleaves the macrophage colony-stimulating factor receptor in macrophages undergoing activation. J Immunol. 2001;166(3):1583-9.
147. Sapi E. The role of CSF-1 in normal physiology of mammary gland and breast cancer: an update. Exp Biol Med. 2004;229(1):1-11.
148. Callahan R, Egan SE. Notch signaling in mammary development and oncogenesis. J Mammary Gland Biol Neoplasia. 2004;9(2):145-63. doi: 10.1023/B:JOMG.0000037159.63644.81.
149. Dontu G, Jackson KW, McNicholas E, Kawamura MJ, Abdallah WM, Wicha MS. Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells. Breast Cancer Res. 2004;6(6):R605-15. doi: 10.1186/bcr920.
150. Resto VA, Burdick MM, Dagia NM, McCammon SD, Fennewald SM, Sackstein R. L-selectin-mediated lymphocyte-cancer cell interactions under low fluid shear conditions. J Biol Chem. 2008;283(23):15816-24. doi: 10.1074/jbc.M708899200.
151. Bendas G, Borsig L. Cancer cell adhesion and metastasis: selectins, integrins, and the inhibitory potential of heparins. Int J Cell Biol. 2012;2012:676731. doi: 10.1155/2012/676731.
152. Arribas J, Lopez-Casillas F, Massague J. Role of the juxtamembrane domains of the transforming growth factor-alpha precursor and the beta-amyloid precursor protein in regulated ectodomain shedding. J Biol Chem. 1997;272(27):17160-5.
153. Coussens LM, Pollard JW. Leukocytes in mammary development and cancer. Cold Spring Harb Perspect Biol. 2011;3(3). doi: 10.1101/cshperspect.a003285.
154. Mukherjee P, Tinder TL, Basu GD, Pathangey LB, Chen L, Gendler SJ. Therapeutic efficacy of MUC1-specific cytotoxic T lymphocytes and CD137 co-stimulation in a spontaneous breast cancer model. Breast Dis. 2004;20:53-63.
155. Zaretsky JZ, Barnea I, Aylon Y, Gorivodsky M, Wreschner DH, Keydar I. MUC1 gene overexpressed in breast cancer: structure and transcriptional activity of the MUC1 promoter and role of estrogen receptor alpha (ERalpha) in regulation of the MUC1 gene expression. Mol Cancer. 2006;5:57. doi: 10.1186/1476-4598-5-57.
156. Mace KF, Ehrke MJ, Hori K, Maccubbin DL, Mihich E. Role of tumor necrosis factor in macrophage activation and tumoricidal activity. Cancer Res. 1988;48(19):5427-32.
157. Fortes GB, Alves LS, de Oliveira R, Dutra FF, Rodrigues D, Fernandez PL, et al. Heme induces programmed necrosis on macrophages through autocrine TNF and ROS production. Blood. 2012;119(10):2368-75. doi: 10.1182/blood-2011-08-375303.
158. Parameswaran N, Patial S. Tumor necrosis factor-alpha signaling in macrophages. Crit Rev Eukaryot Gene Expr. 2010;20(2):87-103.
159. Rappolee DA, Mark D, Banda MJ, Werb Z. Wound macrophages express TGF-alpha and other growth factors in vivo: analysis by mRNA phenotyping. Science. 1988;241(4866):708-12.
160. Walz TM, Malm C, Nishikawa BK, Willander K, Wingren S, Wasteson A. Production of transforming growth factor alpha by human leukemia cells (HL-60 and U-937) during monocytic differentiation. Leukemia. 1995;9(4):671-6.
161. Stanic B, Pandey D, Fulton DJ, Miller FJ Jr. Increased epidermal growth factor-like ligands are associated with elevated vascular nicotinamide adenine dinucleotide phosphate oxidase in a primate model of atherosclerosis. Arterioscler Thromb Vasc Biol. 2012;32(10):2452-60. doi: 10.1161/ATVBAHA.112. 256107.
162. Zeyda M, Farmer D, Todoric J, Aszmann O, Speiser M, Gyori G, et al. Human adipose tissue macrophages are of an anti-inflammatory phenotype but capable of excessive pro-inflammatory mediator production. Int J Obes. 2007;31(9):1420-8. doi: 10.1038/sj.ijo.0803632.
163. Ueno K, Koga T, Kato K, Golenbock DT, Gendler SJ, Kai H, et al. MUC1 mucin is a negative regulator of toll-like receptor signaling. Am J Respir Cell Mol Biol. 2008;38(3):263-8. doi: 10.1165/rcmb.2007-0336RC.
164. Paine R 3rd, Morris SB, Jin H, Baleeiro CE, Wilcoxen SE. ICAM-1 facilitates alveolar macrophage phagocytic activity through effects on migration over the AEC surface. Am J Physiol Lung Cell Mol Physiol. 2002;283(1):L180-7. doi: 10.1152/ajplung.00430.2001.
165. Robker RL, Collins RG, Beaudet AL, Mersmann HJ, Smith CW. Leukocyte migration in adipose tissue of mice null for ICAM-1 and Mac-1 adhesion receptors. Obes Res. 2004;12(6):936-40. doi: 10.1038/oby.2004.114.
166. Lange-Sperandio B, Cachat F, Thornhill BA, Chevalier RL. Selectins mediate macrophage infiltration in obstructive nephropathy in newborn mice. Kidney Int. 2002;61(2):516-24. doi: 10.1046/j.1523-1755.2002.00162.x.
167. Putz EF, Mannel DN. A role for L-selectin in monocyte activation by Jurkat tumour cells. Scand J Immunol. 1996;44(6):556-64.
168. Buisson S, Triebel F. LAG-3 (CD223) reduces macrophage and dendritic cell differentiation from monocyte precursors. Immunology. 2005;114(3):369-74. doi: 10.1111/j.1365-2567.2004.02087.x.
169. Oflazoglu E, Stone IJ, Gordon KA, Grewal IS, van Rooijen N, Law CL, et al. Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30. Blood. 2007;110(13):4370-2. doi: 10.1182/blood-2007-06-097014.
170. Andreesen R, Brugger W, Lohr GW, Bross KJ. Human macrophages can express the Hodgkin's cell-associated antigen Ki-1 (CD30). Am J Pathol. 1989;134(1):187-92.
171. Andrade RM, Portillo JA, Wessendarp M, Subauste CS. CD40 signaling in macrophages induces activity against an intracellular pathogen independently of gamma interferon and reactive nitrogen intermediates. Infect Immun. 2005;73(5):3115-23. doi: 10.1128/IAI.73.5.3115- 3123.2005.
172. Suttles J, Stout RD. Macrophage CD40 signaling: a pivotal regulator of disease protection and pathogenesis. Semin Immunol. 2009;21(5):257-64. doi: 10.1016/j.smim.2009.05.011.
173. Briso EM, Dienz O, Rincon M. Cutting edge: soluble IL-6R is produced by IL-6R ectodomain shedding in activated CD4 T cells. J Immunol. 2008;180(11):7102-6.
174. Truman LA, Ford CA, Pasikowska M, Pound JD, Wilkinson SJ, Dumitriu IE, et al. CX3CL1/fractalkine is released from apoptotic lymphocytes to stimulate macrophage chemotaxis. Blood. 2008;112(13):5026-36. doi: 10.1182/blood-2008-06- 162404.
175. Miksa M, Amin D, Wu R, Ravikumar TS, Wang P. Fractalkine-induced MFG-E8 leads to enhanced apoptotic cell clearance by macrophages. Mol Med. 2007;13(11-12):553-60. doi: 10.2119/2007-00019.Miksa.
176. Zhang L, Ran L, Garcia GE, Wang XH, Han S, Du J, et al. Chemokine CXCL16 regulates neutrophil and macrophage infiltration into injured muscle, promoting muscle regeneration. Am J Pathol. 2009;175(6):2518-27. doi: 10.2353/ajpath.2009. 090275.
177. Borst O, Munzer P, Gatidis S, Schmidt EM, Schonberger T, Schmid E, et al. The inflammatory chemokine CXC motif ligand 16 triggers platelet activation and adhesion via CXC motif receptor 6-dependent phosphatidylinositide 3-kinase/Akt signaling. Circ Res. 2012;111(10):1297-307. doi: 10.1161/CIRCRESAHA.112.276444.
178. Stellos K, Panagiota V, Gnerlich S, Borst O, Bigalke B, Gawaz M. Expression of junctional adhesion molecule-C on the surface of platelets supports adhesion, but not differentiation, of human CD34 cells in vitro. Cell Physiol Biochem. 2012;29(1-2):153-62. doi: 10.1159/000337596.
179. Nedvetzki S, Sowinski S, Eagle RA, Harris J, Vely F, Pende D, et al. Reciprocal regulation of human natural killer cells and macrophages associated with distinct immune synapses. Blood. 2007;109(9):3776-85. doi: 10.1182/blood-2006-10-052977.
180. Fridman JS, Caulder E, Hansbury M, Liu X, Yang G, Wang Q, et al. Selective inhibition of ADAM metalloproteases as a novel approach for modulating ErbB pathways in cancer. Clin Cancer Res. 2007;13(6):1892-902. doi: 10.1158/1078-0432.CCR-06-2116.
181. Witters L, Scherle P, Friedman S, Fridman J, Caulder E, Newton R, et al. Synergistic inhibition with a dual epidermal growth factor receptor/HER-2/neu tyrosine kinase inhibitor and a disintegrin and metalloprotease inhibitor. Cancer Res. 2008;68(17):7083-9. doi: 10.1158/0008-5472.CAN-08-0739.
182. Hundhausen C, Misztela D, Berkhout TA, Broadway N, Saftig P, Reiss K, et al. The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion. Blood. 2003;102(4):1186-95. doi: 10.1182/blood-2002-12-3775.
183. von Marschall Z, Scholz A, Cramer T, Schafer G, Schirner M, Oberg K, et al. Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J Natl Cancer Inst. 2003;95(6):437-48.
184. Sessa C, De Braud F, Perotti A, Bauer J, Curigliano G, Noberasco C, et al. Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. J Clin Oncol. 2005;23(9):1867-74. doi: 10.1200/JCO.2005.09. 032.
185. Takano S, Aramaki Y, Tsuchiya S. Physicochemical properties of liposomes affecting apoptosis induced by cationic liposomes in macrophages. Pharm Res. 2003;20(7):962-8.
186. Lewen S, Zhou H, Hu HD, Cheng T, Markowitz D, Reisfeld RA, et al. A Legumain-based minigene vaccine targets the tumor stroma and suppresses breast cancer growth and angiogenesis. Cancer Immunol Immunother. 2008;57(4):507-15. doi: 10.1007/s00262-007-0389-x.
187. Banciu M, Schiffelers RM, Fens MH, Metselaar JM, Storm G. Anti-angiogenic effects of liposomal prednisolone phosphate on B16 melanoma in mice. J Control Release. 2006;113(1):1-8. doi: 10.1016/j.jconrel.2006.03.019.